<DOC>
	<DOCNO>NCT01690143</DOCNO>
	<brief_summary>This study patient multiple myeloma come back relapse condition indicate procedure call Autologous Hematopoietic Stem Cell Transplantation ( AHSCT ) . AHSCT procedure stem cell bone marrow blood remove high-dose chemotherapy . Afterwards , remove stem cell put back patient 's body form new population blood cell . The high-dose chemotherapy administer AHSCT call `` Conditioning Therapy . '' The FDA approve use drug melphalan condition therapy . This research study look whether add study drug call carfilzomib improve participant outcome . Carfilzomib consider investigational approved FDA treatment relapse multiple myeloma . This study divide two phase . Phase I : Dose Escalation Phase : The main purpose Part I study examine safety study drug , carfilzomib , determine safe amount study drug give subject multiple myeloma . Subjects study receive different dose level study drug . If one first three subject receive study drug , call 'starting dose ' study low dose expect tolerate base prior research . After first set participant receive study drug , study doctor review health see tolerate treatment . This decide study drug dosage increase decreased next set subject join study . It anticipate 12- 18 participant enroll Phase I portion study . Phase II : Safety Confirmation Phase : Once study doctor discover high possible dose study drug subject tolerate , 28 subject may enrol dose level . The main purpose Phase II portion study look effective combination carfilzomib melphalan give stem cell transplantation treat multiple myeloma . This expansion phase also include evaluation two single agent carfilzomib maintenance therapy regimens patient without disease progression day 100 .</brief_summary>
	<brief_title>Carfilzomib + High Dose Melphalan Preparative Regimen Autologous Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>This phase 1/2a trial . Since AHSCT condition regimen trial , one cycle therapy administer subject . PHASE 1 The phase 1 component typical 3+3 design . - Initially three subject enrol cohort start cohort 0 table . - If dose limit toxicity ( DLT ) note among 3 initial subject , 3 additional patient accrue subsequent cohort . - If 1/3 subject experience DLT , 3 additional subject accrue cohort . If additional DLT occur , accrual continue subsequent cohort . - If 2 subject experience DLT give cohort , dose consider high maximum tolerate dose ( MTD ) immediately low dose consider MTD . - If accrual complete cohort 4 0/3 1/6 DLT , MTD consider `` reach '' cohort 4 expand phase 2 trial . - If 2 subject experience DLTs cohort 0 , patient accrue cohort -1 , one subject time , subsequent subject accrue current subject complete DLT period ( transplant day 30 ) . The dos cohort -1 consider MTD 0/3 1/6 subject experience DLT . - If ≥ 2 subject experience DLT cohort -1 study interrupt without proceed phase 2a combination carfilzomib high dose melphalan consider toxic . PHASE 2 Once MTD combination carfilzomib high dose melphalan AHSCT find , expansion MTD cohort 28 individual treat MTD carfilzomib high dose melphalan . Screening - Subjects likely meet eligibility criterion offer participation study investigator verifies registration system current available slot ( phase 1 ) . Subjects sign inform consent prior protocol associated procedure . Screening procedure outline Table 3 1 ) ensure subject meet eligibility criterion , 2 ) obtain disease assessment allow efficacy measurement , 3 ) ass baseline toxicity 4 ) provide initial biological sample pharmacodynamic correlative study . Treatment- Subjects receive appropriate dose carfilzomib ( accord assign cohort phase 1 determine MTD phase 2 ) day -3 -2 . Carfilzomib infuse 30 minute . On day -2 , 60 120 minute end infusion carfilzomib , subject receive 200 mg/m2 intravenous melphalan intravenous push fast infusion . Prophylaxis chemotherapy induce nausea vomit follow institutional guideline . Infusion autologous cells- Infusion autologous hematopoietic stem cell occur day 0 follow institutional SOP . Follow phase - On day 1 follow HSCT patient receive pegfilgrastim 6 mg subcutaneously per institutional standard care aim faster engraftment . The follow phase last 100 day consist standard post transplantation supportive care monitor adverse event ( AE 's ) . For phase 1 component study , dose-limiting toxicity capture first 30 day transplantation ( DLT period ) . Patients without progression may continue carfilzomib maintenance therapy . Patients either randomized block two either maintenance therapy Arm 1= AB ( two cycle A follow two cycle B ) , maintenance therapy Arm 2= BA ( two cycle B follow two cycle A ) . Maintenance regimen A consist carfilzomib 36 mg/m2 infuse 30 minute day 1,8,15 . Maintenance regimen B consist carfilzomib 36 mg/m2 infuse 30 minute day 1 , 2 , 15 16 . Each cycle 4 week duration . The first four maintenance therapy cycle dictate randomized assignment time study registration maintenance therapy . For maintenance therapy arm , patient preference questionnaire administer patient upon completion 4th cycle . The remain 8 cycle ( cycle 5-12 ) administer accord regimen schedule prefer patient documented patient preference questionnaire . Disease assessment- Disease assessment occur day 100 ( +/- 7 day ) consist serum protein electrophoresis , serum urine immunofixation , 24h urine protein electrophoresis , serum free light chain , bone marrow aspiration biopsy , complete blood count metabolic panel .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Age ≥ 18 year ≤ 70 year 2 . Life expectancy ≥ 12 month 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 4 . Diagnosis symptomatic multiple myeloma , relapse initial therapy . 5 . At least minimal response ( defined 25 % decrease M protein serum urine ) recent treatment regimen . 6 . Evaluable disease prior recent treatment regimen define least one following : Serum monoclonal ( M ) protein ≥0.5 g/dl protein electrophoresis 200 mg M protein urine 24 hour electrophoresis Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis ≥30 % 7 . Adequate hepatic function , serum ALT ≤ 3.5 time upper limit normal serum direct bilirubin ≤ 2 mg/dL ( 34 µmol/L ) within 14 day prior start therapy 8 . Hemoglobin ≥ 8 g/dL ( 80 g/L ) within 14 day prior registration ( subject may receive red blood cell [ RBC ] transfusion accordance institutional guideline ) 9 . Creatinine clearance ( CrCl ) ≥ 40 mL/minute within 14 day prior registration , either measure calculate use standard formula ( eg , Cockcroft Gault ) . 10 . Prior storage least 2 x 106 CD34+ cells/kg available autologous transplantation . During phase 1 component study , least amount cell require `` back '' unlikely event nonengraftment . 11 . Subjects may prior AHSCT treatment MM long perform great 12 month study registration . 12 . Subjects must meet institutional general eligibility criteria autologous transplantation . 13 . Written inform consent accordance federal , local , institutional guideline . 14 . Female childbearing potential ( FCBP ) must agree ongoing pregnancy test practice contraception . 15 . Male subject must agree practice contraception . 1 . Pregnant lactating female . 2 . Major surgery within 30 day prior start treatment . 3 . Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior registration . 4 . Known human immunodeficiency virus infection . 5 . Active hepatitis B C infection . 6 . Unstable angina myocardial infarction within 4 month prior registration , NYHA Class III IV heart failure , uncontrolled angina , history severe coronary artery disease , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker . 7 . Uncontrolled hypertension uncontrolled diabetes within 14 day prior registration . 8 . Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas . 9 . Significant neuropathy ( Grades 34 , Grade 2 pain ) within 14 day prior registration . 10 . Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) . 11 . Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior registration . 12 . Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>